Cited 7 times in
Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이충근 | - |
dc.date.accessioned | 2022-12-22T02:19:46Z | - |
dc.date.available | 2022-12-22T02:19:46Z | - |
dc.date.issued | 2022-06 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191532 | - |
dc.description.abstract | The use of anti-programmed cell-death protein (ligand)-1 (PD-[L]1) is an important strategy for treating hepatocellular carcinoma (HCC). However, the treatment only benefits 10-20% of patients when used as a monotherapy. Therefore, the selection of patients for anti-PD-1/PD-L1 treatment is crucial for both patients and clinicians. This review aimed to explore the existing literature on tissue or circulating markers for the identification of responders or non-responders to anti-PD-1/PD-L1 in HCC. For the clinically available markers, both etiological factors (viral versus non-viral) and disease extent (intra-hepatic vs. extrahepatic) impact the responses to anti-PD-1/PD-L1, warranting further studies. Preliminary data suggested that inflammatory indices (e.g., neutrophil-lymphocyte ratio) may be associated with clinical outcomes of HCC during the anti-PD-1/PD-L1 treatment. Finally, although PD-L1 expression in tumor tissues is a predictive marker for multiple cancer types, its clinical application is less clear in HCC due to the lack of a clear-cut association with responders to anti-PD-1/PD-L1 treatment. Although all translational markers are not routinely measured in HCC, recent data suggest their potential roles in selecting patients for anti-PD-1/PD-L1 treatment. Such markers, including the immune classification of HCC, selected signaling pathways, tumor-infiltrating lymphocytes, and auto-antibodies, were discussed in this review. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | CANCERS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma? | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Choong-Kun Lee | - |
dc.contributor.googleauthor | Stephen L Chan | - |
dc.contributor.googleauthor | Hong Jae Chon | - |
dc.identifier.doi | 10.3390/cancers14133213 | - |
dc.contributor.localId | A03259 | - |
dc.relation.journalcode | J03449 | - |
dc.identifier.eissn | 2072-6694 | - |
dc.identifier.pmid | 35804984 | - |
dc.subject.keyword | anti-programmed cell-death protein (ligand)-1 | - |
dc.subject.keyword | clinical biomarker | - |
dc.subject.keyword | hepatocellular carcinoma | - |
dc.subject.keyword | immune checkpoint inhibitor | - |
dc.subject.keyword | predictive biomarker | - |
dc.subject.keyword | translational biomarker | - |
dc.contributor.alternativeName | Lee, Choong-kun | - |
dc.contributor.affiliatedAuthor | 이충근 | - |
dc.citation.volume | 14 | - |
dc.citation.number | 13 | - |
dc.citation.startPage | 3213 | - |
dc.identifier.bibliographicCitation | CANCERS, Vol.14(13) : 3213, 2022-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.